A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs ACT 709478 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 08 Jan 2018 Planned End Date changed from 28 Nov 2017 to 15 Mar 2018.
- 08 Jan 2018 Planned primary completion date changed from 28 Nov 2017 to 15 Mar 2018.
- 26 Jul 2017 Status changed from not yet recruiting to recruiting.